KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors | Zendy

David S. Hong | Zendy; Marwan Fakih | Zendy; John H. Strickler | Zendy; Jayesh Desai | Zendy; Gregory A. Durm | Zendy; Geoffrey I. Shapiro | Zendy; Gerald S. Falchook | Zendy; Timothy Price | Zendy; Adrian G. Sacher | Zendy; Crystal S. Denlinger | Zendy; YungJue Bang | Zendy; Grace K. Dy | Zendy; John C. Krauss | Zendy; Yasutoshi Kuboki | Zendy; James Kuo | Zendy; Andrew L. Coveler | Zendy; Keunchil Park | Zendy; Tae Won Kim | Zendy; Fabrice Barlési | Zendy; Pamela N. Münster | Zendy; Suresh S. Ramalingam | Zendy; Timothy F. Burns | Zendy; Funda MericBernstam | Zendy; Haby Henary | Zendy; Jude Ngang | Zendy; Gataree Ngarmchamnanrith | Zendy; June Myung Kim | Zendy; Brett E. Houk | Zendy; Jude Ca | Zendy; J. Russell Lipford | Zendy; Gregory Friberg | Zendy; Piro Lito | Zendy; Ramaswamy Govindan | Zendy; Bob T. Li | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

KRAS^G12C Inhibition with Sotorasib in Advanced Solid Tumors

Author(s) -

David S. Hong,

Marwan Fakih,

John H. Strickler,

Jayesh Desai,

Gregory A. Durm,

Geoffrey I. Shapiro,

Gerald S. Falchook,

Timothy Price,

Adrian G. Sacher,

Crystal S. Denlinger,

YungJue Bang,

Grace K. Dy,

John C. Krauss,

Yasutoshi Kuboki,

James Kuo,

Andrew L. Coveler,

Keunchil Park,

Tae Won Kim,

Fabrice Barlési,

Pamela N. Münster,

Suresh S. Ramalingam,

Timothy F. Burns,

Funda MericBernstam,

Haby Henary,

Jude Ngang,

Gataree Ngarmchamnanrith,

June Myung Kim,

Brett E. Houk,

Jude Ca,

J. Russell Lipford,

Gregory Friberg,

Piro Lito,

Ramaswamy Govindan,

Bob T. Li

Publication year - 2020

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa1917239

Subject(s) - kras , radiochemistry , nuclear medicine , cancer research , chemistry , computer science , medicine , cancer , colorectal cancer

No therapies for targeting KRAS mutations in cancer have been approved. The KRAS p.G12C mutation occurs in 13% of non-small-cell lung cancers (NSCLCs) and in 1 to 3% of colorectal cancers and other cancers. Sotorasib is a small molecule that selectively and irreversibly targets KRAS G12C .

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research